Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049361 | 0.89 | KDM4E (0.45) | AKR1C3CNR2EPHX2EPHX1KMT2A | |
| SCHEMBL28204197 | 0.87 | AKR1C3 (0.49) | AKR1C3KMT2AALDH1A1TEAD1TEAD3 | |
| SCHEMBL19041082 | 0.85 | CHEK2 (0.40) | AKR1C3EPHX2EPHX1TEAD1TEAD3 | |
| SCHEMBL12545725 | 0.84 | CHRM4 (0.39) | AKR1C3EPHX2EPHX1TEAD1TEAD3 | |
| SCHEMBL27270756 | 0.84 | AKR1C3 (0.47) | AKR1C3KMT2AALDH1A1TEAD1TEAD3 | |
| SCHEMBL19049434 | 0.82 | AKR1C3 (0.46) | AKR1C3EPHX2EPHX1ALDH1A1 | |
| SCHEMBL12801183 | 0.82 | ALDH1A1 (0.43) | EPHX2EPHX1ALDH1A1TEAD1TEAD3 | |
| SCHEMBL12522395 | 0.82 | AKR1C3 (0.46) | AKR1C3ALDH1A1 | |
| SCHEMBL23716464 | 0.81 | CHRNB2 (0.41) | AKR1C3KMT2A | |
| SCHEMBL4550273 | 0.81 | CYP4F2 (0.41) | EPHX2EPHX1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | AKR1C3 1064/4885CNR2 4058/4885EPHX2 2200/4885 |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | AKR1C3 4091/4885CNR2 4205/4885EPHX2 2474/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | AKR1C3 3887/4885CNR2 4883/4885EPHX2 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.